Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes

被引:58
作者
Chandra, D
Jackson, EB
Ramana, KV
Kelley, R
Srivastava, SK
Bhatnagar, A
机构
[1] Univ Louisville, Cardiovasc Res Ctr, Dept Med, Div Cardiol, Louisville, KY 40202 USA
[2] Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77550 USA
关键词
D O I
10.2337/diabetes.51.10.3095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased glucose utilization by aldose reductase (AR) has been implicated in the development of diabetes complications. However, the mechanisms that regulate AR during diabetes remain unknown. Herein we report that several nitric oxide (NO) donors prevent ex vivo synthesis of sorbitol in erythrocytes obtained from diabetic or nondiabetic rats. Compared with erythrocytes of nondiabetic rats, the AR activity in the erythrocytes of diabetic rats was less sensitive to inhibition by NO donors or by AR inhibitors-sorbinil or tolrestat. Treatment with N-G-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthesis, enhanced AR activity and sorbitol accumulation in tissues of nondiabetic rats. Application of transdermal nitroglycerin patches or treatment with L-arginine did not inhibit AR activity or sorbitol accumulation in the tissues of nondiabetic animals. Treatment with L-NAME increased, whereas treatment with L-arginine or nitroglycerine patches decreased AR activity and sorbitol content in tissues of diabetic rats. These observations suggest that NO maintains AR in an inactive state and that this repression is relieved in diabetic tissues. Thus, increasing NO availability may be a useful strategy for inhibiting the polyol pathway and preventing the development of diabetes complications.
引用
收藏
页码:3095 / 3101
页数:7
相关论文
共 44 条
[1]   Nitric oxide synthases: structure, function and inhibition [J].
Alderton, WK ;
Cooper, CE ;
Knowles, RG .
BIOCHEMICAL JOURNAL, 2001, 357 (03) :593-615
[2]   ALDOSE REDUCTASE - CONGENIAL AND INJURIOUS PROFILES OF AN ENIGMATIC ENZYME [J].
BHATNAGAR, A ;
SRIVASTAVA, SK .
BIOCHEMICAL MEDICINE AND METABOLIC BIOLOGY, 1992, 48 (02) :91-121
[3]   HUMAN PLACENTAL ALDOSE REDUCTASE - ROLE OF CYS-298 IN SUBSTRATE AND INHIBITOR BINDING [J].
BHATNAGAR, A ;
LIU, SQ ;
UENO, N ;
CHAKRABARTI, B ;
SRIVASTAVA, SK .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1205 (02) :207-214
[4]  
BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825
[5]   The clinical pharmacology of L-arginine [J].
Böger, RH ;
Bode-Böger, SM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :79-99
[6]   Specifically targeted modification of human aldose reductase by physiological disulfides [J].
Cappiello, M ;
Voltarelli, M ;
Cecconi, I ;
Vilardo, PG ;
Dal Monte, M ;
Marini, I ;
DelCorso, A ;
Wilson, DK ;
Quiocho, FA ;
Petrash, JM ;
Mura, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (52) :33539-33544
[7]   Active site modification of aldose reductase by nitric oxide donors [J].
Chandra, A ;
Srivastava, S ;
Petrash, JM ;
Bhatnagar, A ;
Srivastava, SK .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1341 (02) :217-222
[8]   Modification of aldose reductase by S-nitrosoglutathione [J].
Chandra, A ;
Srivastava, S ;
Petrash, JM ;
Bhatnagar, A ;
Srivastava, SK .
BIOCHEMISTRY, 1997, 36 (50) :15801-15809
[9]   ACTIVATION OF ALDOSE REDUCTASE FROM HUMAN-TISSUES [J].
DAS, B ;
SRIVASTAVA, SK .
DIABETES, 1985, 34 (11) :1145-1151
[10]   Nitric oxide may be required to prevent hypertension at the onset of diabetes [J].
Fitzgerald, SM ;
Brands, MW .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 279 (04) :E762-E768